Unless you have a terminal then the code won't work. it's BI BRPHRM RX RXW:RX_06805
Anyway, market share is steady to down. Last 4 weeks average 13.7%, 3Q was 13.9%, 2Q 14.3%, PCP 13.6%.
T market is down, Axiron largely following it. No market share gains apparent since beginning of 2013.
Maybe if the FDA review signals no problem with labelling and the court cases come to nothing? Otherwise no chance of milestone payments or even growth I'd suggest!
Total retail prescriptions (Count) - source bloomberg
Add to My Watchlist
What is My Watchlist?
